CG
QTTB icon

Carlyle Group’s Q32 Bio QTTB Stock Holding History

Carlyle Group’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$769K Sell
60,363
-1,042,378
-95% -$8.71M 0.01% 13
2026
Q1 		$7.08M Hold
1,102,741
– – 0.07% 7
2025
Q4 		$3.62M Hold
1,102,741
– – 0.03% 8
2025
Q3 		$2.13M Hold
1,102,741
– – 0.05% 12
2025
Q2 		$1.62M Hold
1,102,741
– – 0.03% 15
2025
Q1 		$1.81M Hold
1,102,741
– – 0.05% 17
2024
Q4 		$3.78M Hold
1,102,741
– – 0.09% 14
2024
Q3 		$48.6M Hold
1,102,741
– – 5.1% 5
2024
Q2 		$19.2M Hold
1,102,741
– – 1.82% 10
2024
Q1 		$18.1M Buy
+1,102,741
New +$15.2M 1.14% 12

Other funds holding QTTB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Carlyle Group's QTTB Position: Q2 2026 in Review

Carlyle Group reduced its Q32 Bio (QTTB) stake by 95% in Q2 2026, selling an estimated $8.71M and leaving 60,363 shares worth $769K. The position accounts for 0.01% of the portfolio, ranked #13.

Carlyle Group first reported a position in QTTB in Q1 2024 and has held it in 10 quarters since. The position peaked at $48.6M in Q3 2024. 72 funds tracked by Wall St. Rank hold QTTB as of Q2 2026.

  • Carlyle Group held 60,363 shares of Q32 Bio worth $769K as of Q2 2026.
  • Carlyle Group sold 1,042,378 Q32 Bio shares in Q2 2026, an estimated $8.71M.
  • Q32 Bio made up 0.01% of Carlyle Group's portfolio in Q2 2026, its #13 holding.
  • Carlyle Group first reported a position in Q32 Bio in Q1 2024 and has held it in 10 quarters since.
  • Carlyle Group's Q32 Bio position peaked at $48.6M in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2026.

Based on Carlyle Group's 13F filing for Q2 2026, filed 7 Aug 2026.